Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

NCT01561430 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01561430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01561430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Lead sponsor
Eli Lilly and Company
Phase
Phase 1/2
Overall status
Terminated
Start date
March 31, 2012
Completion date
August 31, 2013
Enrollment
70 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease